Sonrotoclax (BGB-11417) in Relapsed or Refractory Mantle Cell Lymphoma: FDA Accelerated Approval Based on Phase I/II Data
Sonrotoclax (BGB-11417; Beqalzi) is a next-generation, highly selective B-cell lymphoma 2 (BCL-2) inhibitor that recently received accelerated approval from the U.S. Food and Drug Administration (FDA) on May 13, 2026, for the treatment of adults with relapsed or refractory mantle cell lymphoma (R/R MCL) after at least two prior lines of systemic therapy, including a […]
